These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 23490655

  • 1. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C, Chemo-N 0 Study Group.
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [Abstract] [Full Text] [Related]

  • 2. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
    Cancer Res; 2002 Aug 15; 62(16):4617-22. PubMed ID: 12183417
    [Abstract] [Full Text] [Related]

  • 3. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.
    Thromb Haemost; 2004 Mar 15; 91(3):450-6. PubMed ID: 14983219
    [Abstract] [Full Text] [Related]

  • 4. High levels of uPA and PAI-1 predict a good response to anthracyclines.
    Borstnar S, Sadikov A, Mozina B, Cufer T.
    Breast Cancer Res Treat; 2010 Jun 15; 121(3):615-24. PubMed ID: 20039121
    [Abstract] [Full Text] [Related]

  • 5. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
    Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N.
    Breast Cancer Res Treat; 2013 Apr 15; 138(3):839-50. PubMed ID: 23568480
    [Abstract] [Full Text] [Related]

  • 6. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M, German N0 Study Group.
    J Natl Cancer Inst; 2001 Jun 20; 93(12):913-20. PubMed ID: 11416112
    [Abstract] [Full Text] [Related]

  • 7. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
    Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C.
    Clin Breast Cancer; 2002 Aug 20; 3(3):196-200. PubMed ID: 12196277
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
    Vénat-Bouvet L, Fermeaux V, Leobon S, Saidi N, Monteil J, Mollard J, Aubard Y, Jammet I, Tubiana-Mathieu N.
    Anticancer Res; 2014 Mar 20; 34(3):1213-7. PubMed ID: 24596362
    [Abstract] [Full Text] [Related]

  • 9. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N, Kates RE, Schmitt M.
    J Clin Oncol; 2002 Feb 15; 20(4):1000-7. PubMed ID: 11844823
    [Abstract] [Full Text] [Related]

  • 10. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
    Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA.
    Clin Breast Cancer; 2004 Dec 15; 5(5):348-52. PubMed ID: 15585071
    [Abstract] [Full Text] [Related]

  • 11. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
    Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N.
    BMC Cancer; 2011 Apr 16; 11():140. PubMed ID: 21496284
    [Abstract] [Full Text] [Related]

  • 12. Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.
    Kolben T, Augustin D, Armbrust R, Kolben TM, Degenhardt T, Burgmann M, Goess C, Ditsch N, Kates R, Harbeck N, Wuerstlein R.
    Breast Cancer Res Treat; 2016 Jan 16; 155(1):109-15. PubMed ID: 26643086
    [Abstract] [Full Text] [Related]

  • 13. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 14. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N, Thomssen C.
    Zentralbl Gynakol; 2003 Sep 01; 125(9):362-7. PubMed ID: 14569518
    [Abstract] [Full Text] [Related]

  • 15. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
    Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, André J, Bobin JY.
    Clin Breast Cancer; 2008 Apr 01; 8(2):168-77. PubMed ID: 18621614
    [Abstract] [Full Text] [Related]

  • 16. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.
    Cancer; 2004 Aug 01; 101(3):486-94. PubMed ID: 15274061
    [Abstract] [Full Text] [Related]

  • 17. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ, Duggan C.
    Clin Biochem; 2004 Jul 01; 37(7):541-8. PubMed ID: 15234235
    [Abstract] [Full Text] [Related]

  • 18. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot AJ, van Tienoven DT, Beex LV, Sweep FC.
    Thromb Haemost; 2004 Mar 01; 91(3):514-21. PubMed ID: 14983227
    [Abstract] [Full Text] [Related]

  • 19. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
    De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, Bollet MA, Reyal F, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X, Magdelénat H, Mignot L, Fourquet A, Breast Cancer Study Group of the Institut Curie.
    Anticancer Res; 2009 May 01; 29(5):1475-82. PubMed ID: 19443353
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun 01; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.